New Test for H pylori Evaluation

Published Online: Thursday, September 1, 2005

Helicobacter pylori infection is linked to approximately 80% and 90% of gastric and duodenal ulcers, respectively. The H pylori stool antigen (HpSA) test is a new tool for evaluating infection. In a recent study, reported in the Journal of Gastroenterology and Hepatology (August 2005), Masanori Ito, MD, and colleagues investigated the clinical usefulness of the HpSA test, compared with the 13C-urea breath test (UBT), in evaluating bacterial eradication therapy. Patients (n = 105) with H pylori infection received appropriate antibiotic eradication therapy (eg, amoxicillin, tetracycline), and the results were evaluated after 8 weeks.

Of these patients, 24% and 19% tested positive with the UBT and the HpSA test, respectively. Discordant results were seen in 8.6% of the patients (7 with UBT+ and HpSA-and 2 with UBT-and HpSA+). Five of the patients were determined to have false-positive results with the UBT. Final diagnostic accuracies of the UBT and the HpSAtests were 94.3% and 97.1%, respectively. In cases of weakly positive UBT values, the HpSA test was used to diagnose the correct status of infection after eradication in 99% of all patients. For the clinical evaluation of eradication therapy, a combination of both tests is recommended.

Latest Articles
Pharmacists are in a great position to impart valuable heart-related wisdom to their patients.
Shifts in sleep schedules may increase an individual’s risk for diabetes.
Qualgen has taken corrective actions concerning its compounding facility conditions and sterility processes.
Mylan has announced the US launch of clozapine orally disintegrating tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical’s FazaClo.
Latest Issues